CAMBRIDGE, Mass., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Gerard Michel, CFO & VP of Corporate Development, will present the latest company overview at the Ladenburg Thalmann 2019 Healthcare Conference in New York on Tuesday, September 24, 2019 at 11:00am Eastern Time.
A live webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com
About Vericel Corporation Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the Unted States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American commercial rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company's website at www.vcel.com.